Lozar Krivec J, Bratina P, Valcl A, Lozar Manfreda K, Petrovčič A, Benedik E, Obermajer T, Bogovič Matijašić B, Šetina U, Rupnik M, Mahnič A, Paro-Panjan D
Department of Neonatology, Division of Paediatrics, University Medical Centre Ljubljana, Zaloška cesta 2, Ljubljana, Slovenia.
Faculty of Medicine, 37664University of Ljubljana, Vrazov trg 2, Ljubljana, Slovenia.
Benef Microbes. 2024 Oct 31;16(2):157-169. doi: 10.1163/18762891-bja00049.
Perinatal antibiotic exposure potentially leads to gut microbiota dysbiosis, which is associated with functional gastrointestinal disorders (FGIDs). We aimed to investigate the effects of Limosilactobacillus reuteri DSM 17938 supplementation on the development of FGIDs, crying and sleep duration, and the gut microbial composition in infants exposed to antibiotics during the neonatal period. In this randomised, double-blind, placebo-controlled study, we included 89 term neonates treated with antibiotics. Neonates received the study product for six weeks. FGIDs, assessed by the Infant Gastrointestinal Symptom Questionnaire, crying and sleep duration were assessed at four and eight weeks, and six months after enrolment. Faecal samples were collected six weeks and twelve months after enrolment. The gut microbial community composition was analysed using 16S amplicon sequencing and qPCR. The proportion of infants with FGIDs was greater in the control group, although the difference between the groups was significant only six months after enrolment. At all time points, the probiotic group presented a longer sleep duration and shorter crying time than the control group, but the difference was not statistically significant. Probiotic consumption had no significant effect on the gut microbiota composition except for increased L. reuteri DSM 17938 abundance in the probiotic group at six weeks after enrolment. At specific time points after supplementation with L. reuteri DSM 17938, a reduction in the prevalence of FGIDs was observed in the probiotic group. However, no observable effect on the gut microbiota was detected during the intervention. We believe that probiotic supplementation in neonates during and after antibiotic treatment to minimise the negative effects of antibiotics on gut function during this vulnerable period of human development warrants further investigation. The trial is registered at ClinicalTrials.gov (NCT02865564).
围产期抗生素暴露可能导致肠道微生物群失调，这与功能性胃肠疾病（FGIDs）有关。我们旨在研究补充罗伊氏乳杆菌DSM 17938对新生儿期暴露于抗生素的婴儿FGIDs的发生、哭闹和睡眠时间以及肠道微生物组成的影响。在这项随机、双盲、安慰剂对照研究中，我们纳入了89名接受抗生素治疗的足月儿。新生儿接受研究产品六周。通过婴儿胃肠道症状问卷评估FGIDs，在入组后四周、八周和六个月评估哭闹和睡眠时间。在入组后六周和十二个月收集粪便样本。使用16S扩增子测序和qPCR分析肠道微生物群落组成。对照组中患有FGIDs的婴儿比例更高，尽管两组之间的差异仅在入组六个月后显著。在所有时间点，益生菌组的睡眠时间比对照组更长，哭闹时间更短，但差异无统计学意义。除了入组六周后益生菌组中罗伊氏乳杆菌DSM 17938丰度增加外，食用益生菌对肠道微生物群组成没有显著影响。在补充罗伊氏乳杆菌DSM 17938后的特定时间点，益生菌组中FGIDs的患病率有所降低。然而，在干预期间未检测到对肠道微生物群的明显影响。我们认为，在抗生素治疗期间和之后对新生儿补充益生菌，以尽量减少抗生素在人类发育这一脆弱时期对肠道功能的负面影响，值得进一步研究。该试验已在ClinicalTrials.gov（NCT02865564）注册。
